LearnGlossaryMarketStocksSuperinvestorsSign in

TEVA

Teva Pharmaceutical Industries Limited

Healthcare · $45.3B market cap

Verdict

We can't put a fair value on TEVA right now. It lost money in at least 2 of its last 3 years, so one year of cash flow isn't a reliable base to value it on.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-0.5% a year✗
Equity per share growth-7.4% a year✗
Sales growth1.5% a year✗
Free cash flow growth-7.0% a year✗
Return on invested capital2.5%✗

Follow TEVA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold TEVA. Who we track

Harry Burn

Sound Shore · as of Q2 2026

$128.9M

3,804,497 shares

David Einhorn

Greenlight Capital · as of Q4 2023

$2.8M

268,470 shares

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works